Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Non-cash Items: 2022-2024

  • Stoke Therapeutics' Non-cash Items fell 49.16% to $4.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.3 million, marking a year-over-year decrease of 49.16%. This contributed to the annual value of $4.3 million for FY2024, which is 6.29% up from last year.
  • Latest data reveals that Stoke Therapeutics reported Non-cash Items of $4.3 million as of Q4 2024, which was down 49.16% from $8.4 million recorded in Q4 2023.
  • In the past 5 years, Stoke Therapeutics' Non-cash Items ranged from a high of $20.6 million in Q4 2022 and a low of $4.3 million during Q4 2024.
  • Moreover, its 3-year median value for Non-cash Items was $8.4 million (2023), whereas its average is $11.1 million.
  • Data for Stoke Therapeutics' Non-cash Items shows a maximum YoY slumped of 59.05% (in 2023) over the last 5 years.
  • Quarterly analysis of 3 years shows Stoke Therapeutics' Non-cash Items stood at $20.6 million in 2022, then slumped by 59.05% to $8.4 million in 2023, then crashed by 49.16% to $4.3 million in 2024.
  • Its last three reported values are $4.3 million in Q4 2024, $8.4 million for Q4 2023, and $20.6 million during Q4 2022.